Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
Sponsor: Marissa Jarosinski
Summary
This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.
Official title: The Value of Screening for "High on Treatment Platelet Reactivity" in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
31
Start Date
2019-08-09
Completion Date
2024-03-28
Last Updated
2026-07-06
Healthy Volunteers
No
Conditions
Interventions
Point of care screening for HPR
HPR testing using VerifyNow testing system. HPR is defined platelet reactivity units are greater than 234
Ticagrelor 90mg
Participants who test positive for HPR will be prescribed ticagrelor 90mg twice daily instead of standard therapy with clopidogrel 75mg daily
Locations (1)
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States